Dual targeted zeolitic imidazolate framework nanoparticles for treating metastatic breast cancer and inhibiting bone destruction

Shen, Yaping; Lv, Yonggang

doi:10.1016/j.colsurfb.2022.112826

Cited by 14 publications

(7 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Subsequently, the pH-responsive ZIF-8 was decomposed to release Cur for medical treatment. The dual-targeted drug-delivery system opens up an available approach to achieve the synergistic therapy for suppressing tumor progression and antibone resorption (entry 22, Table 1) [89]. These investigations confirm ZIFs are a class of potential nanocarriers for controlled drug delivery and release.…”

Section: Other Mofsmentioning

confidence: 75%

See 1 more Smart Citation

Recent Advances in Metal–Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release

et al. 2022

View full text Add to dashboard Cite

Metal–organic frameworks (MOFs) have a good designability, a well-defined pore, stimulus responsiveness, a high surface area, and a controllable morphology. Up to now, various MOFs have been widely used as nanocarriers and have attracted lots of attention in the field of drug delivery and release because of their good biocompatibility and high-drug-loading capacity. Herein, we provide a comprehensive summary of MOF-based nanocarriers for drug delivery and release over the last five years. Meanwhile, some representative examples are highlighted in detail according to four categories, including the University of Oslo MOFs, Fe-MOFs, cyclodextrin MOFs, and other MOFs. Moreover, the opportunities and challenges of MOF-based smart delivery vehicles are discussed. We hope that this review will be helpful for researchers to understand the recent developments and challenges of MOF-based drug-delivery systems.

show abstract

Section: Other Mofsmentioning

confidence: 75%

“…copyright (2021) the American Chemical Society, Ref [88],. copyright (2019) the American Chemical Society, and Ref [89],. copyright (2022) Elsevier.…”

mentioning

confidence: 99%

Recent Advances in Metal–Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Preparation of DCLMZ: LM NPs were synthesized using an ultrasound strategy based on the previous study. [31] After the large particles were removed by centrifugation, CTAB (25 mg), deionized water (8 mL), NH 3 •H 2 O (170 μL), TEOS (80 μL), APTES (6 μL), and dopamine (3 mg) were successively added into the solution, and the ultrasound was continued for 2 h. Then, the NPs (LM@MP) were collected by centrifugation (12 000 rpm, 10 min) and washed with water and ethanol three times. The LM@MP was then dispersed in a 1% sodium chloride methanol solution and stirred overnight to remove the template.…”

Section: Methodsmentioning

confidence: 99%

“…The HA/ALN conjugate was successfully constructed as described in our previous study. [31,32] HA/ALN-modified NPs could act as a "guide" to facilitate NPs to first reach the tumor metastatic bone, and then be taken up by CD44-receptor overexpressed tumor cells. The effects of mild PTT combined with Cur on drug penetration and antitumor efficacy were evaluated using in-vitro biological experiments.…”

Section: Introductionmentioning

confidence: 99%

Hierarchically Released Liquid Metal Nanoparticles for Mild Photothermal Therapy/Chemotherapy of Breast Cancer Bone Metastases via Remodeling Tumor Stromal Microenvironment

Shen

Zou

Bie

et al. 2023

Adv Healthcare Materials

Self Cite

View full text Add to dashboard Cite

Currently, the treatment strategy for bone metastasis is mainly to inhibit the growth of tumor cells and the activity of osteoclasts, while ignoring the influence of the tumor stromal microenvironment (TSM) on the progression of bone metastasis. Herein, a dual‐target liquid metal (LM)‐based drug delivery system (DDS) with favorable photothermal performance is designed to spatially program the delivery of multiple therapeutic agents to enhance the treatment of bone metastasis through TSM remodeling. Briefly, mesoporous silicon‐coated LM is integrated into zeolitic imidazolate framework‐8 (ZIF‐8) with both bone‐seeking and tumor‐targeting capacities. Curcumin (Cur), a tumor microenvironment modulator, is encapsulated into ZIF‐8, and doxorubicin (DOX) is enclosed inside mesoporous silicon. Specific accumulation of the LM‐based DDS in bone metastases first relieves the tumor stroma by releasing Cur in response to the acidic tumor microenvironment and then releases DOX deep into the tumor under near‐infrared light irradiation. The combined strategy of the LM‐based DDS and mild photothermal therapy has been shown to effectively restrain cross‐talk between osteoclasts and tumor cells by inhibiting the secretion of transforming growth factor‐β, degrading extracellular matrix components, and increasing infiltration of CD4+ and CD8+ T cells, which provides a promising strategy for the treatment of bone metastases.

show abstract

“…Lu et al 152 showed that co-delivery of cyclobenzaprine and adriamycin using albumin NPs targeted primary BC and metastatic lymph nodes and inhibited tumor metastasis in vivo. Shen et al 59 developed a bone and tumor dual-targeting nanocarrier using an NF-κB inhibitor in zeolitic imidazolate backbone-8. These dual-targeted NPs aggregate in the bone under the guidance of bone-targeted ligands, and the modified cellular ligands contribute to NP absorption in cancer cells.…”

Section: Nps In Bc and Skeletal System Drug Therapymentioning

confidence: 99%

Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges

Yu,

Zhu

2024

IJN

View full text Add to dashboard Cite

Although the frequency of bone metastases from breast cancer has increased, effective treatment is lacking, prompting the development of nanomedicine, which involves the use of nanotechnology for disease diagnosis and treatment. Nanocarrier drug delivery systems offer several advantages over traditional drug delivery methods, such as higher reliability and biological activity, improved penetration and retention, and precise targeting and delivery. Various nanoparticles that can selectively target tumor cells without causing harm to healthy cells or organs have been synthesized. Recent advances in nanotechnology have enabled the diagnosis and prevention of metastatic diseases as well as the ability to deliver complex molecular “cargo” particles to metastatic regions. Nanoparticles can modulate systemic biodistribution and enable the targeted accumulation of therapeutic agents. Several delivery strategies are used to treat bone metastases, including untargeted delivery, bone-targeted delivery, and cancer cell-targeted delivery. Combining targeted agents with nanoparticles enhances the selective delivery of payloads to breast cancer bone metastatic lesions, providing multiple delivery advantages for treatment. In this review, we describe recent advances in nanoparticle development for treating breast cancer bone metastases.

show abstract

Dual targeted zeolitic imidazolate framework nanoparticles for treating metastatic breast cancer and inhibiting bone destruction

Cited by 14 publications

References 29 publications

Recent Advances in Metal–Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release

Recent Advances in Metal–Organic-Framework-Based Nanocarriers for Controllable Drug Delivery and Release

Hierarchically Released Liquid Metal Nanoparticles for Mild Photothermal Therapy/Chemotherapy of Breast Cancer Bone Metastases via Remodeling Tumor Stromal Microenvironment

Nanoparticles for the Treatment of Bone Metastasis in Breast Cancer: Recent Advances and Challenges

Contact Info

Product

Resources

About